Ocoxin oral solution demonstrates antiviral properties in cellular models

Exp Ther Med. 2021 Oct;22(4):1127. doi: 10.3892/etm.2021.10561. Epub 2021 Aug 5.

Abstract

Ocoxin Oral Solution (OOS) and Viusid (VS) are nutritional supplements that include several natural products which affect different cellular functions, such as proliferation or the redox status. In addition, some of their constituent components have been described to exert an antiviral effect. Considering this, it was hypothesized that treatment with OOS and VS could protect from viral infections. In order to evaluate the impact of OOS and VS on viral infection, lentivirus and retrovirus whose genomes coded for green fluorescent protein were used. In addition, and as a second approach to measure viral infection, a hemagglutinin-tagged form of the mitogen-activated protein kinase ERK5 was also inserted in the retroviral vector. Viral particles produced in 293T cells were used to infect HeLa cells in the presence or absence of OOS or VS. It was observed that VS had a minimal effect on the capacity of either lentivirus or retrovirus to infect HeLa cells. However, OOS significantly reduced the infection of HeLa cells with both of these viruses. The effect was dose-dependent, reaching a maximum at a 1:100 dilution of OOS. These results suggested that, in addition to its well-known antitumoral properties, OOS may also inhibit infection with viruses. This effect is relevant since patients receiving oncological therapies are more susceptible to viral infections, and nutritional supplements such as OOS may help in reducing the severity of these potential pathogenic infections.

Keywords: Ocoxin; Viusid; antiviral; nutritional supplement; viral infection.

Grants and funding

Funding: AP is a staff employee of the Spanish Research Council (CSIC) and EDR is supported by a postdoctoral contract from the same institution. ES is an employee of Catalysis S.L. The work on ocoxin oral solution in preclinical models carried out by AP and EDR has received partial support from Catalysis S.L.